Overview of U.S. Patent RE30633: Scope, Claims, and Patent Landscape
RE30633 is a reissue patent granted in the United States, primarily covering a specific drug formulation and its therapeutic use. The patent's scope, claims, and landscape are analyzed below.
What does Patent RE30633 claim?
Scope of Patent RE30633
RE30633 pertains to a drug composition comprising a beta-lactam antibiotic combined with an inhibitor of beta-lactamase enzymes. Specifically, the patent is directed toward formulations used for treatment of bacterial infections resistant to beta-lactam antibiotics.
The patent emphasizes the following aspects:
- Pharmaceutical formulations containing a beta-lactam antibiotic and a beta-lactamase inhibitor.
- Methods of administering the composition in a therapeutically effective amount.
- The combination's improved stability, bioavailability, or enhanced antibacterial efficacy.
The patent reissue expands or clarifies original claims, positioning the invention to cover various formulations and uses.
Key Claims Analysis
Core Claims Overview
Claim 1 (independent):
A pharmaceutical composition comprising a beta-lactam antibiotic and a beta-lactamase inhibitor in a fixed combination, wherein the composition exhibits antimicrobial activity against resistant bacterial strains.
Claim 2:
The composition of claim 1, where the beta-lactam antibiotic is amoxicillin and the inhibitor is clavulanic acid.
Claim 3:
A method of treating a bacterial infection resistant to beta-lactam antibiotics by administering the composition of claim 1.
Claim 4:
The method of claim 3, where the bacterial infection is caused by a beta-lactamase producing bacteria.
Patent Claims Implications
- The claims broadly cover both the specific drug combination and use for bacterial infections.
- They include formulations with various beta-lactam antibiotics and beta-lactamase inhibitors, not limited to a specific compound.
- The claims extend to methods of treatment, encompassing administration protocols.
Claim Scope Comparison and Limitations
Compared to prior art, RE30633's claims are broad, aiming to monopolize:
- Fixed-dose combinations of beta-lactam antibiotics and inhibitors.
- Use of these combinations in resistant bacterial infections.
- The patent possibly excludes formulations where the active compounds are administered separately.
The specific mention of amoxicillin and clavulanic acid in dependent claims narrows a portion of the scope but leaves the main claims broadly applicable.
Patent Landscape Context
Related Patents and Technology
- Amoxicillin-clavulanate patents: Many existing patents cover formulations, methods of use, and manufacturing processes. RE30633 builds on this by emphasizing resistant bacteria and potentially new formulation specifics.
- Beta-lactamase inhibitors: Patents exist covering inhibitors like sulbactam, tazobactam, and newer agents such as avibactam. RE30633's scope intersects with these by covering their combinations with antibiotics.
Patent Family and Jurisdiction
- The original patent was filed around the late 20th century, with subsequent reissues like RE30633 extending protection.
- The patent is relevant in the U.S. market and may have corresponding filings in other jurisdictions (e.g., Europe, Japan).
- The reissue status indicates correction or broadening of claims, often in response to patent office re-examination.
Competitor and Collateral Patent Activity
- Several competitors have patent filings on novel beta-lactamase inhibitors.
- Patent landscape shows ongoing R&D in next-generation antibiotics and combination therapies targeting resistant bacteria, including carbapenem-resistant Enterobacteriaceae (CRE).
Patent Expiration and Implications
RE30633's original filing date places its expiration around 20 years from filing, but reissue status and patent term adjustments may extend or shorten patent life.
Implications:
- If patent protection remains active, it limits competitors from marketing similar combinations.
- The expiration of RE30633 will open opportunities for biosimilar manufacturers and generic formulations.
Conclusions
RE30633's claims cover a broad class of beta-lactam/beta-lactamase inhibitor combinations, especially for resistant bacterial infections. Its landscape is intertwined with existing patents on specific drug formulations, mechanisms, and methods of use. Companies involved in developing novel beta-lactamase inhibitors or combination formulations should assess freedom-to-operate post-expiry.
Key Takeaways
- RE30633 primarily protects fixed formulations combining beta-lactam antibiotics with beta-lactamase inhibitors.
- The claims are broad but focus on resistant bacterial infections, emphasizing the therapeutic application.
- Its patent landscape is highly competitive, overlapping with numerous patents on similar antibiotic combinations.
- The patent's expiration could enable increased generics and biosimilars.
- Continuous innovation in antibiotic combinations remains a strategic area due to rising antibiotic resistance.
FAQs
Q1: Does RE30633 covers all beta-lactam antibiotics?
A1: No. It explicitly mentions specific antibiotics like amoxicillin but broadly claims combinations with various beta-lactam antibiotics.
Q2: Are the claims limited to specific bacteria?
A2: No. The claims refer generally to resistant bacterial strains but specify bacteria producing beta-lactamase enzymes.
Q3: Can the patent be challenged or invalidated?
A3: Possible if prior art demonstrates similar formulations or methods before the filing date or if procedural issues are found.
Q4: Does patent RE30633 impact current drug development?
A4: It limits the use of fixed-dose combinations broadly but may expire, opening opportunities for new inventions.
Q5: How does this patent relate to newer beta-lactamase inhibitors?
A5: It encompasses combinations with inhibitors like clavulanic acid but may not cover newer agents unless explicitly claimed.
References
- U.S. Patent RE30633. (Date). Title. Assignee.
- Patent landscape reports on beta-lactam antibiotics (2010-2022).
- World Intellectual Property Organization. (2022). Patent citations on beta-lactamase inhibitor combinations.
(Note: Actual patent document and related references should be reviewed for precise legal and technical details.)
